Business
InflaRx Reports Full Year 2021 Financial and Operating Results
Company received corrected FDA advice letter for Phase III trial with vilobelimab in hidradenitis suppurativaPositive Phase IIa data reported with vilobelimab
About this update from Inflarx N.v.
[{"type":"text","content":"Company received corrected FDA advice letter for Phase III trial with vilobelimab in hidradenitis suppurativaPositive Phase IIa data reported with vilobelimab in pyoderma gangrenosum; data being presented as late-breaker oral presentation at AAD Annual MeetingTopline data in vilobelimab Phase III trial in severe COVID-19 expected by end of MarchBoth US and EU Phase II trials with vilobelimab in AAV met their objectivesPhase II trial with vilobelimab in cSCC enrolling with first efficacy data expected later this yearNew program, INF904 oral small molecule inhibitor of C5aR, recently introducedYear-end cash and cash equivalents of approximately €26.2 million and financial assets of approximately €84.4 million JENA, Germany, March 24, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial and operating results for the year ended December 31, 2021. Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, commented: “We have made important progress in broadening and advancing our development activities over the course of 2021 and into 2022. This includes introducing a new program, the oral small molecule C5aR inhibitor, INF904, and moving vilobelimab into a new indication, cutaneous small cell carcinoma. In addition, we reported promising results with vilobelimab in pyoderma gangrenosum and ANCA-associated vasculitis, and we now await the Phase III topline results in our COVID-19 trial. We are hopeful for a positive outcome but, either way, we believe the results will help to further the overall understanding of this devastating disease.” He continued, “We are thankful for the corrected advice letter from the FDA related to vilobelimab development in hidradenitis suppurativa and will clarify our path forward in this debilitating disease in the coming months. We expect a busy year ahead as we work towards our goal of developing treatments to control inflammation and improve the lives of patients suffering from neutrophil-driven diseases.” Recent Highlights and R&D Update Vilobelimab for Hidradenitis Suppurativa (HS) In February 2022, the Company received an advice letter from the FDA related to its Phase III program and its IND. The feedback to the clinical protocol indicate...